Aricept holds up for Eisai in first half
This article was originally published in Scrip
Executive Summary
Good growth for mainstay product Aricept (donepezil), particularly in the US, helped push Eisai's group net sales up by 4% to ¥412.3 billion ($5.07 billion) in the first half ended 30 September.